Rosemary Mazanet M.D. Ph.D. age 51 has served as a director since October 2001 and currently serves on the Nominating and Corporate Governance Committee. Dr. Mazanet has served as the Chief Executive Officer of Breakthrough Therapeutics LLC a therapeutic development company since February 2004. She also served as acting Chief Executive Officer of Access Pharmaceuticals (AMEX: AKC) from May 2005 to February 2006. From June 1998 to February 2004 Dr. Mazanet served as Chief Scientific Officer and a General Partner of Oracle Partners L.P. a hedge fund. Prior to joining Oracle Partners Dr. Mazanet served as the Director of Clinical Research at Amgen Inc. a pharmaceutical company. Dr. Mazanet is a member of the Board of Trustees of the University of Pennsylvania School of Medicine. She trained in internal medicine at the Brigham and Women’s Hospital and in oncology at the Dana Farber Cancer Institute both part of the Harvard Medical system where she was a staff physician prior to joining Amgen. Dr. Mazanet holds a B.A. in Biology from the University of Virginia and an M.D. and a Ph.D. from the University of Pennsylvania. |